In the INDIGO trial, presented by Mellinghoff et al at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, researchers tested the efficacy of vorasidenib, an oral dual inhibitor of mutant IDH1/2 enzymes, in patients with brain tumors (Abstract LBA1).
